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Abstract  
Immunotherapy holds great promise for treatment of infectious and 
malignant diseases and might help to prevent the occurrence and 
recurrence of cancer. We produced a plant-derived tumor-associated 
colorectal cancer antigen EpCAM (pGA733) at high yields using two 
modern plant expression systems. The full antigenic domain of EpCAM 
was efficiently purified to confirm its antigenic and immunogenic 
properties as compared to those of the antigen expressed in the 
baculovirus system (bGA733). Recombinant plant-derived antigen 
  
induced a humoral immune response in BALB/c mice. Sera from those 
mice efficiently inhibited the growth of SW948 colorectal carcinoma cells 
xenografted in nude mice, as compared to the EpCAM-specific mAb CO17-
1A. Our results support the feasibility of producing anti-cancer 
recombinant vaccines using plant expression systems.  
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Abbreviations  
TAA Tumor-associated antigen 
EpCAM/GA733 Colorectal cancer-associated antigen 
bGA733  Baculovirus-derived GA733-2  
pGA733  Plant-derived GA733-2  
mAb  Monoclonal antibodies  
 
 
Introduction  
The concept of cancer vaccination as a preventive measure is of 
increasing interest to oncology in view of advances in modern molecular 
biology and biotechnology [7, 14, 15]. Several anti-cancer vaccines for 
the treatment of minimal residual disease are currently in human clinical 
  
trials [6, 21]. The T- and B-cell immune responses against tumor-
associated antigens (TAA) could lead to efficient elimination of tumor cells 
without harming the surrounding normal tissue, as well as help to 
generate long-lasting immunological memory against tumor recurrences, 
as already shown in humans and animals [8]. There is also strong 
evidence supporting the use of recombinant antigen vaccines, either 
alone, or in combination with hormonal, chemotherapeutic and 
monoclonal antibody approaches, to treat colorectal cancer [1, 5, 19, 22, 
26].  
 
The use of plant biotechnology to produce pharmaceutical and industrial 
proteins has clear economic scalability and safety advantages as 
compared to traditional microbial and mammalian production systems [9, 
11, 12, 16, 17]. Plants offer potentially very high expression level of 
recombinant proteins [10, 11]. However, the main advantage of plant-
based expression systems is lack of harmful or even lethal contaminants 
(viruses, toxins, prions, oncogenes) that might contaminate other 
production systems [2, 9–12]. Current efforts are focused on maximizing 
expression levels and accumulation of functional plant-produced proteins, 
preferably in soluble form to facilitate purification [4, 5, 10, 11, 13, 23]. 
We previously expressed the GA733-2 antigen in planta using a tobacco 
mosaic virus-based system. Although, mice immunized with the plant-
produced product demonstrated an antigen-specific immune response, 
  
small amounts of plant-derived material precluded complete 
immunological assessment [26].  
The use of modern transient and stable plant transformation systems 
now allows the high yield production of GA733-2 TAA in plants. We found 
that fusion to the endoplasmic reticulum (ER) retaining signal led to 
increased levels of protein accumulation in plant cells, and an efficient 
immuno-affinity purification procedure yielded EpCAM antigen (pGA733) 
in sufficient amounts to confirm its protective immunogenicity in mice. 
Antigen-specific serum antibodies from these mice inhibited tumor cell 
growth in xenografted nude mice. Our results confirm the utility of plants 
in high-yield and inexpensive production of drugs for cancer 
immunotherapy.  
 
Materials and methods  
 
EpCAM expression cassette design  
 
A DNA fragment of GA733-2 antigen extracellular domain (aa 24–264) 
[20, 25] was amplified by the following primers: F-5′-
CCATGGCTCAGGAAGAATGTGTCTGT-3′ and R-5′-
GTCGACTTTATCATCATCATCAAGATCTTTTAG ACCCTGCATTGAGAATTCA-
3′, which carry NcoI and BglII sites, respectively. The product was 
cloned into the pGEMT vector (Promega, Madison, WI, USA), sequence-
verified, and recloned into plasmid pBIV-1.3Tag (Plant Research 
  
International, Wageningen, NL, USA) comprised of the RbcS1 promoter, 
C-terminal tags (c-myc and His
6
) and the KDEL retention ER signal. The 
resulting expression cassette was transferred (AscI/PacI) into the plant 
binary vector pBIN-Plus (Plant Research International), resulting in 
plasmid pRB74, which was placed into Agrobacterium tumefaciens strain 
LBA4404 for stable plant transformation. The GA733 NcoI/SacI fragment 
from the pBIV-based construct was recloned into the carrier pro-vector 
plasmid pICH11599 (Icon Genetics, Haale (Saale), Germany) and placed 
in Agro-strain GV3101 for vacuum-infiltration “magnifection” of wild type 
Swiss chard plants.  
 
Transient and constitutive plant transformation  
 
For rapid production of recombinant antigen, we used the magnifection 
procedure [10, 11, 13, 18]. Agro-cultures carrying the expression 
cassette were mixed with cultures carrying pre-manufactured helper 
plasmids (pICH14011 and pICH17620) (Icon Genetics) and applied to 
mature (6– 8 weeks old) Beta vulgaris var. cicla (Swiss chard) plants. 
Plant tissues were harvested after 7–10 days and analyzed by Western 
blot and ELISA. Low-alkaloid Nicotiana tabacum cv. LAMD609 (tobacco) 
(Oxford Tobacco Research Station, Oxford, NC) was used for leaf explants 
agro-mediated transformation [5] with pRB74. Independent transgenic 
lines were selected in medium containing kanamycin (100 mg/l) and used 
  
for molecular characterization.  
 
Isolation and purification of plant (p) GA733 protein  
 
Plant leaf tissues were collected and processed as described [5, 13]. After 
centrifugation, supernatants were additionally successively clarified 
through a Miracloth (Calbiochem, La Jolla, CA, USA) and a 0.45-µm filter 
(Millipore, Bedford, MA, USA). Soluble protein extract was applied on a 
murine mAb Ab733-immobilized HighTrap column (Amersham, 
Piscataway, NJ, USA) or purified using His
6 
and c-myc tags as described 
[13]. Eluates of recombinant pGA733 protein were combined, dialyzed 
against PBS buffer and brought to a final concentration 1 mg/ml using 
Amicon Ultra spin-column with a 10-kDa cut-off (Millipore). Aliquots were 
frozen in liquid nitrogen and stored at 
¡
80°C. For analysis extracts were 
resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and either 
stained or transferred to a nitrocellulose membrane (Bio-rad, Hercules, 
CA, USA), blocked with 5% non-fat milk and incubated with murine c-myc 
mAb (Calbiochem, San Diego, CA, USA) or mAb Ab733 followed by 
secondary anti-mouse Fc-specific Ab conjugated to horseradish 
peroxidase (Sigma, St Louis, MO, USA) diluted 1:10,000. Reactive protein 
bands were visualized using chemiluminescent substrate for peroxidase 
(Pierce, Rockford, IL, USA).  
 
  
Immunological analysis of pGA733 in mice  
 
Eight-week-old female BALB/c mice (five per group) were injected with 
three doses (5 µg) of pGA733 in a total volume of 100 µl at 2-week 
intervals. First and second immunizations were given subcutaneously 
(s.c.) with complete and incomplete Freund’s adjuvant (Difco, Detroit, MI, 
USA), respectively; the third dose was administered inter-peritoneally 
(i.p.) in saline. Control groups received 5 µg per injection of baculovirus-
produced bGA733 (kindly provided by Dr William Wunner, Wistar 
Institute, Philadelphia, PA, USA) or total soluble protein extract (TSP) 
from non-transgenic wild-type plants. Blood samples were collected by 
retro-orbital bleeding before experiment and 10 days after the second 
immunization; 10 days after the third immunization, mice were sacrificed 
and bled by cardiac puncture. Sera were analyzed by ELISA and Western 
blotting. ELISA for bGA733 (1 µg/ml in PBS) was performed essentially as 
described [23]. Antigen-specific antibodies were detected using goat anti-
mouse IgG (BD Biosciences, San Jose, CA, USA), goat anti-mouse IgG2b 
and IgG3 (Bethyl Labs, Montgomery, TX, USA) and rat anti-mouse IgG1 
and IgG2a (BD Biosciences). Results are presented as mean ±SD.  
 
Inhibition of tumor growth in vivo  
 
Human colorectal carcinoma cells SW948 were maintained according to 
  
the supplier’s instructions (ATCC) in DMEM supplemented with 10% FBS. 
Six-to-8-week-old BALB/c nu/nu mice (5 per group) (Charles River 
Laboratories, Wilmington, MA, USA) were inoculated s.c. with 10
6 
cells on 
the back of the neck followed immediately by four i.p. injections at 3-day 
intervals with 100 µl of serum from pGA733 or bGA733 immunized 
BALB/c mice for a total of 400 µl during 7 days. Control groups were 
injected with 100 µl of TSP serum or 100 µg of mAb CO17-1A (Centocor, 
Horsham, PA, USA) using the same regimen. Tumor growth was recorded 
at 10, 15, 17, 19, 22, 24, 26, 29, 31, 35 and 38 days after initial injection 
and calculated based on the three major diameters measured with 
graduated calipers. At the end of the experiment, mice were euthanized 
by CO
2 
inhalation in accordance with the institutional guidelines for animal 
welfare.  
Results  
 
Production and puriWcation of pGA733 (EpCAM)  
 
cDNA of the extracellular domain of antigen GA733 (aa 24–264) was 
inserted into the pBIV-1.3Tag vector as a translational fusion with the ER 
signal peptide; c-myc and His
6
 tag epitopes and the ER retention signal 
KDEL (Plant Research International) were attached to the GA733 C-ter-
minus. The antigen expression cassette containing promoter and 
  
termination signal was placed in the pBINPlus binary vector, yielding the 
construct pRB74 (Fig. 1a). EpCAM coding sequence (except ER signal 
peptide) was subcloned into the magnICON Icon Genetics’ plasmid 
pICH115999 (Fig. 1a) and used for transient expression of pGA733 [11, 
13, 18].  
The magnifection technique provided a robust and rapid way to express 
recombinant pGA733 transiently in a large biomass plant, such as Swiss 
chard (Fig. 1b, left). The recombinant protein was readily detected by 
Western blotting at 7–9 days, post-infection in transfected leaf tissues 
(Fig. 1b, right).  
Several stably transformed transgenic tobacco lines selected based on 
kanamycin resistance (Fig. 1c, left) showed detectable amounts of 
pGA733 in leaf extracts on Western blot analysis (Fig. 1c, right). 
Quantitative ELISA indicated a variable level of recombinant antigen 
expression with up to 10 mg/kg of fresh leaves (not shown). The 
transgenic line with the highest detectable antigen amount was self-
crossed to obtain a homozygous line.  
The GA733 protein remained stable in fresh and lyophilized plant tissues 
at ambient temperatures or at 4°C and was used to obtain standardized 
samples at purity suitable for immunization (Fig. 1d). Plant-derived 
antigen was purified from tobacco and Swiss chard plants by single step 
antigen-specific immunoaffinity chromatography and/or by two-step 
  
affinity tag-specific technique, yielding ~5 mg of pGA733 from 1 kg of 
fresh leaf tissue as verified by SDSPAGE (Fig. 1d, left) and quantitative 
ELISA. Equal amounts of plant and baculovirus produced GA733, as 
determined by protein assay, produced bands of similar intensity on 
coomassie gel and western blot and the same OD in quantitative ELISA 
with monoclonal antibodies against GA733. Purified product resolved as a 
double-band (both ~30 kDa) with a few additional minor bands confirmed 
to be subproducts of pGA733 by immunostaining analysis (right). The 
purity of plant-derived antigen as visualized on SDS-PAGE is ~60% (left). 
Note that migration of the plant-derived protein was slower than that of 
bGA733 (Fig. 1d), possibly reXecting the presence of the cmyc and His
6
 
tags and the KDEL peptide.  
 
Immune response of mice injected with pGA733  
 
All mice injected with pGA733 or bGA733 antigen mounted a strong 
GA733-speciWc serum antibody response, with comparable titers after 
either immunization as tested in ELISA against plant- and baculovirus-
derived antigen (Fig. 2a). As expected, both IgG1 and IgG2a/b subclasses 
were present in the sera, with slight predominance of IgG1 (Fig. 2b). 
Western blotting confirmed the serum specificity of anti-GA733 antibodies 
in mice immunized with bGA733 or pGA733 (Fig. 2c).  
Suppression of tumor growth in mice by plant-derived vaccine  
  
 
In nude mice xenografted with SW948 colorectal cancer cells and treated 
with plant TSP serum, the first signs of tumor appeared 10 days after 
injection; thereafter, tumors grew rapidly, averaging 1,357 mm
3
 by day 
38 (Fig. 3). The first signs of tumor appeared by day 15 in mice treated 
with pGA733 and bGA733 sera and by day 22 in mice treated with mAb 
CO17-1A (Fig. 3a). In bGA733-treated group, all mice developed tumors, 
although development was significantly delayed in two mice. In the mAb 
CO17-1A treated group, two mice remained tumor-free for the 38-day 
observation period. At 38 days, mean tumor volumes of both pGA733 and 
bGA733-treated mice were significantly lower than that of the TSP control 
group (P < 0.0001) (Fig. 3a, b). One mouse in pGA733 group remained 
tumor free throughout the 38-day observation period. In control plant 
TSP sera-treated group, all mice developed tumors (Fig. 3b, bottom). 
 
Discussion  
 
Several TAAs have been identified and their immune interactions in 
patients have been well characterized. In numerous cases, immune 
approaches to the treatment of cancer have entered the clinical stage [6, 
21]. The EpCAM TAA, which has been studied for more than 20 years, is 
one of the best-described candidates for active immunotherapy of 
colorectal cancer [20].  
  
In the last 2 decades, the use of plants for production of a range of 
different therapeutics has been explored [9, 12, 16, 17]. Our recent 
comparison of the immune response induced by GA733 produced in 
baculovirus-infected insect cell culture versus GA733 produced in planta 
using a viral vector [26] revealed a similar antibody response to both 
antigens in mice, with similar tumor cell specificity in in vitro assay. 
However, the low expression level in this prevented comparison of the 
anti-cancer activity of the mouse in vivo.  
In this study, we used modern plant production schemes [5, 13] to 
efficiently express the EpCAM TAA. High-yield production was achieved 
using the “ImpactVector system”, which is using the strong RbcS1 
promoter from Chrysanthemum and allows direction of antigen expression 
into specific plant cell compartments. Fusion of c-myc and His
6 
tags, as 
well as the ER retention signals KDEL to the C-terminus of GA733 
facilitated detection and purification of the antigen. Furthermore, using 
this expression cassette, we produced considerable amounts of pGA733-
expressing leaf biomass using rapid and robust magnification of the 
vegetable plant Swiss chard. Recombinant antigen was expressed at 
levels of 5–10 mg/kg of fresh leaf material.  
The recombinant pGA733 was readily extracted from the pooled leaf 
material in soluble form. Transgenic T
0 
tobacco plants with the highest 
expression level were processed in a one-step, immunoaffinity-based 
  
purification procedure that resulted in ~50% recovery of recombinant 
antigen from plant tissue (~5 mg/kg). Although transient expression and 
double-step purification was even more efficient, stably transformed low-
alkaloid tobacco appears to be more economically feasible.  
The immune response to pGA733 appeared to be the same or only 
slightly weaker than that of an equal dose of bGA733 in BALB/c mice. It 
seems unlikely that differential reactivity, e.g., due to different 
glycosylation patterns in pGA733 and bGA733, underlies this observation, 
since similar results were obtained in ELISA with either antigen. 
Moreover, Western blot analysis of mouse sera against pGA733 and 
bGA733 at 1:10,000 dilutions revealed similar patterns, indicating high 
purity of both antigens. Reactivity of anti-pGA733 sera appeared to be in 
this case a bit higher with pGA733 compared to bGA733 (Fig. 2c). In 
earlier analyses of the immunological properties of pGA733 using QS21 as 
adjuvant, we observed a predominantly IgG1 response [26], whereas in 
the present study we detected a higher percentage of IgG2a/b antibodies 
in sera of mice immunized with either pGA733 or bGA733, although IgG1 
antibodies remained a prominent subclass (Fig. 2b). This is likely due to 
the use of Freund’s adjuvant.  
Sera from mice immunized with pGA733, bGA733 or mAb CO17-1A 
demonstrated significant inhibition of tumor growth in comparison to TSP 
control sera in xenografted nude mice. There were no significant 
  
differences between sera from mice immunized with pGA733 or bGA733 
in tumor growth inhibition in vivo. The mAb CO17-1A sera had some 
advantage over pGA733 and bGA733 sera during the early period (days 
15–19) but the difference became insignificant later on (days 22–38) (Fig. 
3a).  
The possibility that pre-assembled antigen-antibody immune complexes 
might have superior immunogenicity [3] awaits analysis using plant-
derived mAb CO17-1A [15] and plant-derived EpCAM antigen.  
Our data clearly demonstrate that pGA733-generated sera display 
comparable in vitro and in vivo activity to the sera generated against the 
bGA733 antigen and can efficiently inhibit tumor growth in vivo. This work 
points to the promise of transgenic plants as an excellent source of anti-
cancer vaccines, particularly in the case of this attractive target—EpCAM 
antigen, which is known to be immunogenic in humans [24].  
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Figures 
 
 
 
Fig. 1 Expression of EpCAM in plants.  
a Colorectal cancer-associated antigen EpCAM/GA733-2 was assembled in 
plant expression vectors pBIN-plus (ImpactVector) and pICH115999 
(MagnICON) for stable and transient plant transformation, respectively. 
The final expression cassette contains: the rubisco small subunit 
promoter, RbcS1, driving the coding sequence of EpCAM antigen; the ER 
signal peptide (SP) and retention signal KDEL; a cassette (nptII) 
conferring resistance to the antibiotic kanamycin, and c-myc and H6 tags. 
  
All components are located within the left (LB) and right (RB) borders of 
TDNA (plasmid pRB74) for stable transformation.  
b Six-week-old Swiss chard plants were used for MagnICON-based 
expression (left).  Soluble pGA733 was detected at 7, 8 and 9 days post 
inoculation (dpi) by Western blotting with antigen-specific mAb in total 
soluble protein (TSP) extracts (right).  
c Stably transformed tobacco plants (left) and Western blotting (right) of 
total protein extract from this plants probed with murine mAb AB733. 
Positive control (+) is the bacteria-expressed GA733 antigen; protein 
extract from non-transgenic wild-type (wt) tobacco served as a negative 
control.  
d SDS-PAGE and Western blotting (at 1:1000 dilution) of soluble pGA733 
affinity-purified from plant leaf tissues compared with purified bGA733. 
Numbers on the left indicate molecular size (kDa). 
 
 
 
 
 
 
 
  
 
 
Fig. 2 Serum antibody response to EpCAM in BALB/c mice.  
a ELISA titers of sera from BALB/c mice immunized with pGA733 or 
bGA733 antigen. Results are presented as mean ±SD.  
b ELISA IgG subclass titers of the pooled pGA733 and bGA733 sera in 
panel a.  
c Serial dilutions of pGA733 and bGA733 protein preparations (1:3) 
probed with the corresponding pooled sera (1:10,000 dilution) obtained 
after the third immunization of mice in panel A.  
 
 
 
  
 
 
 
 
Fig. 3 Suppression of tumor growth in nude mice by pGA733-specific 
antibodies.  
a BALB/c nu/nu mice xenografted with 10
6 
SW948 colorectal cancer cells 
were injected with serum from BALB/c mice immunized with either 
pGA733 or bGA733 antigen, or received serum from mock-immunized 
(plant TSP) mice, or murine mAb CO17-1A. At days 2, 4 and 7, all mice 
were injected with three additional doses of sera or antibodies. Tumor 
volumes (mm
3
) were recorded at 10, 15, 17, 19, 22, 24, 26, 29, 31, 35 
  
and 38 days after initial inoculation with cancer cells. Data are given as 
mean ±SD.  
b Pictures of mice treated with pGA733 sera (top) or control plant TSP 
sera (bottom) were taken on day 35 after injection of tumor cells. Tumor 
areas are circled; arrows indicate tumor cell injection sites. 
 
 
